Pulmonary Embolectomy System Market

The global pulmonary embolectomy system market is projected to total USD 1.51 billion in 2026, advancing to USD 3.39 billion by 2036, achieving a CAGR of 8.4%. This expansion is driven by the rising global incidence of pulmonary embolism, particularly massive and submassive cases, alongside significant technological advancements that favor minimally invasive interventions.

Summary of PulmonaryEmbolectomySystem Market

• Market Snapshot
  • Global pulmonaryembolectomysystem market revenue stood at USD 1.51 billion in 2026 and is forecast to reach USD 3.39 billion by 2036.
  • Ata8.4%CAGRfrom 2026 to 2036, this market is set to expand ~2.2x in value, adding USD 1.88 billion in absolute opportunity.
  • This marketrepresentsa high-growth interventional cardiology and vascular device segment, driven by increasing incidence of pulmonary embolism (PE), particularly acute and life-threatening cases.
  • Pulmonaryembolectomysystems are evolving toward minimally invasive catheter-based technologies, reducing procedural risk, recovery time, and dependence on open surgery.
• Demand and Growth Drivers
  • Rising global incidence of pulmonary embolism (massive andsubmassivePE) is the primary growth driver.
  • Increasing adoption of minimally invasive catheter-based interventions is accelerating market expansion.
  • Growing demand for rapid clot removal solutions in emergency and critical care settings is supporting adoption.
  • Advancements in interventional cardiology and vascular technologies are improving safety, precision, and procedural outcomes.
  • Expansion of hospital-based interventional infrastructure (cathlabs, hybridORs) is enabling wider adoption of advancedembolectomysystems.
• Product and Segment View
  • Catheter-basedembolectomysystems hold 48.0% of product share in 2026,emergingas the dominant segment due to reduced invasiveness and faster recovery.
  • Massive pulmonary embolism (PE) accounts for 55.0% of application share in 2026, positioning it as the leading segment due to urgent intervention requirements.
  • Hospitalsrepresent76.0% of end-user share in 2026, reflecting the need for specialized infrastructure and multidisciplinary care teams.
  • Key product categories include:
    • Catheter-basedembolectomysystems
    • Surgicalembolectomysystems
    • Aspirationthrombectomydevices
• Geography and Competitive Outlook
  • Growth is supported across North America, Europe, and Asia Pacific, driven by healthcare infrastructure, disease prevalence, and technological adoption.
  • United States (10.2%CAGR), India (9.6%), China (9.4%), United Kingdom (8.8%), Germany (8.7%), and France (8.6%) are key growth markets.
  • Market expansion is closely tied to:
    • Increasing cardiovascular disease burden
    • Expansion of interventional cardiology procedures
    • Adoption of minimally invasive surgical techniques
  • Competitive landscape includes companies focused on:
    • Catheter-based clot removal systems
    • Aspiration andthrombectomytechnologies
    • Advanced interventional device platforms

PulmonaryEmbolectomySystem Market — At a Glance

The market is dominated by catheter-based embolectomy systems, reflecting a clinical shift away from open surgery towards percutaneous techniques that reduce patient trauma and improve recovery times. Growth is further concentrated in hospital settings, which house the necessary multidisciplinary teams and advanced imaging infrastructure. USA leads in growth rate due to its advanced healthcare infrastructure and high procedural volume, while emerging economies like India and China present significant opportunities due to improving access to interventional care. The competitive landscape features specialized device innovators competing with large, diversified medtech corporations, with success hinging on demonstrating superior clinical outcomes, procedural efficiency, and robust training support.

By Product, Which Technology is Redefining First-Line Intervention?

Catheter-based embolectomy systems command a leading 48.0% share. This dominance is due to their minimally invasive profile, which allows for rapid thrombus removal in critically ill patients who are poor candidates for open surgery or thrombolytic drugs. Their ability to restore pulmonary blood flow quickly, reducing right heart strain, has established them as a cornerstone of modern PE response.

By Application, Which Condition Represents the Most Critical Procedural Demand?

Massive PE constitutes the dominant application with a 55.0% share. This life-threatening condition, characterized by hypotension and cardiogenic shock, creates an urgent need for immediate thrombus removal to prevent mortality. The high mortality risk associated with massive PE drives the adoption of advanced embolectomy systems as essential, time-critical tools in emergency and cardiac care units.

By End User, Where is Complex Acute Care Centralized?

Hospitals are the primary end-user segment, holding a 76.0% share. Tertiary care hospitals and academic medical centers possess the hybrid operating rooms, advanced interventional radiology/cardiology suites, and multidisciplinary teams including intensivists, interventionalists, and cardiac surgeons required to diagnose and perform emergent embolectomy procedures around the clock.

What Distinguishes Germany's Integration of Research and Standardized Care Pathways?

Germany's 8.7% CAGR is propelled by its robust network of university hospitals that serve as both high-volume treatment centers and research hubs for clinical trials. Adoption of advanced embolectomy systems is accelerated through standardized national care pathways (DMPs) and a reimbursement system that recognizes the value of innovative, evidence-based interventions. Growth is further driven by the country’s strong medical device sector, fostering close collaboration between clinicians and domestic engineers on device refinement.

How Does France's Centralized Health System Streamline Technology Adoption?

France's 8.6% CAGR is underpinned by its highly centralized public health system, which facilitates the rapid dissemination of new clinical guidelines from agencies like the HAS (Haute Autorité de Santé). This structure allows for coordinated adoption of proven technologies across regional university hospitals (CHUs).

Government-led tenders and a focus on health technology assessment, ensuring that new embolectomy systems demonstrate clear clinical and economic benefit before widespread integration into publicly funded care pathways, characterize market growth.

What Drives the USA's Advanced Interventional Capability and Procedural Volume?

The USA's 10.2% CAGR is propelled by its high prevalence of risk factors for PE, a well-established network of comprehensive stroke and cardiac centers, and favorable reimbursement for complex interventional procedures. Early adoption of innovative catheter-based technologies and a strong clinical research ecosystem further solidify its position as the largest and most advanced market.

How is India's Healthcare Modernization Expanding Access to Acute Interventions?

India's 9.6% CAGR is linked to rapid expansion in private hospital chains equipped with advanced cath labs and a growing cadre of trained interventional cardiologists and radiologists. Increasing awareness and diagnosis of PE, coupled with rising healthcare investments, are making advanced embolectomy procedures accessible beyond major metropolitan centers.

What Strategic Healthcare Investments Underpin China's Market Growth?

China's 9.4% CAGR is driven by massive government investment in upgrading county-level hospital infrastructure and building regional cardiovascular centers. The rising burden of cardiovascular disease and a focus on improving acute care standards are generating significant demand for advanced medical devices, including embolectomy systems, with growing domestic manufacturing playing a supportive role.

What Role Does the UK's National Health Service and Research Play?

The National Health Service’s (NHS) procurement pathways influence the UK’s 8.8% CAGR and the influence of national guidelines from bodies like NICE. Growth is tied to clinical evidence generation from UK-based research and the systematic adoption of cost-effective technologies that demonstrate improved patient outcomes and reduced overall hospitalization costs.

The competitive landscape features intense rivalry between specialized thrombectomy companies and large cardiovascular device corporations. Competition centers on clinical data demonstrating superiority in complete clot removal, procedure speed, and safety outcomes.

Key Strategic Pillars for Market Players

• Inari Medical
• Penumbra
• Boston Scientific
• Medtronic plc.
• Cook Medical
• Others

• American Heart Association. (2025). Guidelines for the management of massive and submassive pulmonary embolism. Circulation.
• Konstantinides, S. V., & Meyer, G. (2024). The 2024 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal.
• Society of Interventional Radiology. (2024). Quality improvement guidelines for percutaneous management of acute pulmonary embolism. Journal of Vascular and Interventional Radiology.
• Tapson, V. F., & Sterling, K. (2025). Advances in catheter-directed therapy for pulmonary embolism. Chest.
• U.S. Food and Drug Administration. (2025). Premarket approval data for mechanical thrombectomy devices.

• Product :

  • Catheter-based embolectomy systems
  • Surgical embolectomy systems
  • Aspiration thrombectomy devices

• Application :

  • Massive PE
  • Submassive PE
  • Chronic PE

• End User :

  • Hospitals
  • Cardiac centers
  • Specialty Clinics

• Region :

  • North America
    • USA
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • BENELUX
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Poland
    • Czech Republic
    • Rest of Eastern Europe
  • East Asia
    • China
    • Japan
    • South Korea
    • Rest of East Asia
  • South Asia & Pacific
    • India
    • ASEAN
    • Australia
    • Rest of South Asia & Pacific
  • MEA
    • GCC Countries
    • South Africa
    • Turkiye
    • Rest of MEA